BioSpace News Archive

Stereotaxis today announced the first patients have been successfully treated utilizing Abbott’s EnSite ™ X EP System with Stereotaxis’ Robotic Magnetic Navigation System.

Polydex Pharmaceuticals Limited held a Special Meeting on July 14, 2023 relating to a Plan of Arrangement involving Polydex Pharmaceuticals Limited, Biospectra International Inc., and Biospectra Canada Inc., that upon shareholder approval, Biospectra would acquire all of the outstanding common and preferred shares of the Company.

Aptevo Therapeutics Inc. today announced that its bispecific AML drug candidate APVO436, in combination with emerging standard of care venetoclax and azacitidine, achieved positive duration of remission results in its Phase 1b dose escalation trial.

Shockwave Medical, Inc. will report financial results for the second quarter 2023 after market close on Monday, August 7, 2023.

Rakuten Medical, Inc. today announced it will host a virtual R&D Day on the preliminary safety and efficacy findings from its open-label Phase 1b/2 study of Alluminox™ treatment using ASP-1929 in combination with anti-PD-1 therapy in recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC).

SYBLEU INC., a biotechnology company focused on therapies for human and animal health, medical devices, and clinical diagnostics, is preparing to begin advancing small molecule drug therapies for animal and human health utilizing recently in-licensed AI/ML technology coupled with co-owned small molecule patents.

Verismo Therapeutics today announced it has raised $17M in a second pre-Series A financing round.

NorthStar Medical Radioisotopes today announced the signing of a supply agreement for the therapeutic medical radioisotope, actinium-225 (Ac-225) with Bayer.

ChromaDex Corp. announced promising findings from two independent clinical study abstracts originally presented this past April at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting.

Genprex, Inc. today announced it has entered into an exclusive license agreement with the University of Pittsburgh.